Curaleaf International
European medical cannabis company and subsidiary of US-based Curaleaf Holdings.
Curaleaf International is a documented medical cannabis operator in Europe with verifiable licensing in the UK, Germany, and Portugal. However, claims about its size relative to competitors are disputed and rarely backed by audited figures. The brand operates only through prescription channels, not direct-to-consumer. Product availability and regulatory compliance vary by country and change frequently. Always verify current licensing, product certificates of analysis, and clinician suitability rather than relying on marketing claims.
What it is
Curaleaf International is the European subsidiary of Curaleaf Holdings, Inc., a US-based multistate cannabis operator [1]. The company is headquartered in London and operates in medical cannabis markets across the United Kingdom, Germany, Italy, Poland, and Portugal.
The business focuses on prescription medical cannabis: cultivation, extraction, manufacturing of pharmaceutical-grade products (mainly dried flower and oils), import/export logistics, and distribution through regulated pharmacy and clinical channels [2][4].
Curaleaf International does not operate in adult-use recreational markets in Europe. While Germany's 2024 cannabis reform (Cannabisgesetz) permits non-medical home cultivation and possession by adults, it does not establish a commercial recreational market in which Curaleaf operates [3].
Ownership and corporate history
Curaleaf International began as EMMAC Life Sciences, a European medical cannabis company founded in 2017 [2]. In April 2021, Curaleaf Holdings announced the acquisition of EMMAC for approximately $286 million in cash and stock, rebranding it as Curaleaf International [2][4].
The acquisition gave Curaleaf Holdings its European footprint, including the Terra Verde cultivation facility in Portugal and established distribution channels in Germany and the UK [2][4]. Curaleaf International remains a wholly owned subsidiary of Curaleaf Holdings. For current capital structure and corporate filings, investors should consult Curaleaf Holdings' disclosures on SEDAR+ (Canadian securities exchange) [1].
Market focus and products
Germany: Curaleaf International's consumer-facing brand in Germany is Adven, which markets prescription medical cannabis flower and oil products through German pharmacies under the German narcotics prescription (BtM-Rezept) framework [5]. Specific product names, cannabinoid profiles, or cultivation details are not independently verified here and should be confirmed via product certificates of analysis and pharmacy records.
United Kingdom: The company supplies medical cannabis to private clinics and pharmacies under the post-2018 specials regime, which allows specialist doctors to prescribe unlicensed cannabis-based products for medicinal use [6]. NHS prescribing of unlicensed cannabis products remains rare.
Portugal: Terra Verde, near Setúbal, is an EU-GMP licensed cultivation and processing facility that supplies flower and extracts to European medical cannabis programs [2].
The company has stated it also serves Italy and Poland's medical cannabis programs. Independent verification of specific product volumes, cultivar availability, or supply agreements is limited.
Reputation and scale — caveats
Curaleaf International is frequently described in industry trade press as a major vertically integrated medical cannabis operator in Europe [2]. However, claims about being "the largest" or specific market-share rankings should be treated with caution Disputed. European medical cannabis markets are fragmented and country-regulated; audited volume and revenue figures are rarely public. Competitors including Tilray Brands, Aurora, Cantourage, and Demecan also make similar claims of scale, but no independent audit agency publishes comparable rankings.
The Adven brand is known to German medical cannabis patients, but patient experience varies, and pharmacy stock of specific cultivars changes frequently based on import cycles and demand.
There are no widely recognised independent quality awards specific to medical cannabis brands in Europe comparable to those in adult-use regulated markets.
Regulatory issues and compliance
In November 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) suspended Curaleaf International's UK manufacturer/importer licence following a compliance inspection; the company subsequently worked with the regulator and the licence was reinstated. This episode is a useful reminder that medical cannabis operators remain subject to ongoing pharmaceutical regulatory scrutiny and that supply continuity is not guaranteed.
Separately, parent company Curaleaf Holdings faced US regulatory action: the FDA issued a warning letter in 2019 regarding CBD product marketing claims [8]. That action concerns the US parent company, not the European subsidiary directly, but it is part of the corporate group's regulatory record.
Profiles of Curaleaf International products and operations should not assume continuous regulatory approval or uninterrupted supply.
Availability and legal-market notes
Curaleaf International products are legally available only through medical cannabis channels in countries where the company holds the relevant licences and where a clinician has issued a prescription. The company does not sell directly to consumers.
Availability of specific cultivars in German pharmacies fluctuates based on import schedules, cultivation cycles, and patient demand. Patients in the UK access products through specialist private clinics, since NHS prescribing remains limited.
Current licensing status with the relevant national regulators (MHRA in the UK, BfArM in Germany, Infarmed in Portugal) should be verified before assuming a product is legally available.
What to verify before relying on brand claims
Before treating any marketing or product claim about Curaleaf International or Adven as fact:
- Check current licensing with the relevant national regulator (MHRA UK, BfArM Germany, Infarmed Portugal).
- Review parent company filings at Curaleaf Holdings investor relations and SEDAR+ for segment-level financial data and licensing updates [1].
- Request a certificate of analysis (COA) for any specific batch; verify cannabinoid content, terpene profiles, and contaminant testing through an accredited laboratory.
- Consult your clinician about whether a Curaleaf or Adven product is appropriate for your condition, rather than relying on brand marketing.
- Confirm pharmacy stock directly with your pharmacy, as availability of specific products changes frequently.
Strain names and cultivar descriptions in cannabis are often marketing terms and are rarely standardised across producers or countries Weak / limited. Do not assume that a product with a particular name from one supplier matches the same name from another.
Profile last verified: October 2026. Licensing, corporate structure, product availability, and regulatory status change frequently in European medical cannabis markets.
Sources
- Government Curaleaf Holdings, Inc. Continuous disclosure filings and issuer profile, SEDAR+ (Canadian securities exchange).
- Reported Jaeger, K. (2021). Curaleaf Announces $286 Million Acquisition Of European Cannabis Company EMMAC Life Sciences. Marijuana Moment, April 2021.
- Government Bundesministerium für Gesundheit (Germany). Cannabisgesetz (CanG) — overview of the 2024 cannabis law reform.
- Reported Schaneman, B. (2021). Curaleaf to acquire EMMAC Life Sciences for $286 million, expanding into Europe. MJBizDaily, April 2021.
- Reported MJBizDaily. Coverage of Adven and German medical cannabis market. Accessed 2023–2026.
- Government UK Medicines and Healthcare products Regulatory Agency (MHRA). Cannabis-based products for medicinal use — regulatory framework.
- Reported Prohibition Partners. European medical cannabis industry reports, 2022–2026.
- Government US Food and Drug Administration. Warning Letter to Curaleaf, Inc., July 22, 2019.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Curaleaf — Multi-state cannabis operator and publicly traded parent of Select and Grassroots brands.
- Tilray Brands — Publicly traded holding company operating cannabis and beverage brands across multiple jur...
- Tilray Portugal — Medical cannabis producer and subsidiary of Tilray Brands operating in Portugal.